Lorlatinib for ALK ‐fused, infant‐type hemispheric glioma with lung metastasis: a case report
Annals of Clinical and Translational Neurology · 2023-05 · 10 (5) · 836-841
DOI: 10.1002/acn3.51766 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 31.03.2023. Verfasst von Mingyao Lai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, 510515, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Glioma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Infant‐type hemispheric glioma, a new subtype of pediatric high‐grade glioma, arises in the cerebral hemispheres. Despite better survival outcomes, the treatment of infant‐type hemispheric glioma is still facing challenges. Here, we reported a case of QKI ‐ ALK fusion, infant‐type hemispheric glioma with lung metastasis who achieved a complete clinical response after lorlatinib treatment. This typical case demonstrated the importance of appropriate molecularly targeted treatments in ALK ‐fused tumors, and lorlatinib may serve as an effective complement to conventional chemotherapy and radiotherapy in primary glioma harboring ALK fusions and its metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, 510515, China.
- Department of Pathology, Guangdong Sanjiu Brain Hospital, Guangzhou, 510515, China.
- Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
- Department of Pathology, Guangzhou Women and Children Medical Center, Guangzhou, 510620, China.
- State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, 210042, China.
- Department of Medicine, Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, 210042, China.
ORCID-Profile: Linbo Cai
Zitieren
APA
Lai, M., Li, S., Li, H., Hu, Q., Li, J., Zhou, J., Ai, R., Zhen, J., Zhou, Z., Wang, L., Zhang, Y., Hu, W., Yuan, L., Ma, X., Zhang, X., Song, C., Li, Z., & Cai, L. (2023). Lorlatinib for ALK ‐fused, infant‐type hemispheric glioma with lung metastasis: a case report. Annals of Clinical and Translational Neurology, 10(5), 836-841. https://doi.org/10.1002/acn3.51766
Vancouver
Lai M, Li S, Li H, Hu Q, Li J, Zhou J, et al. Lorlatinib for ALK ‐fused, infant‐type hemispheric glioma with lung metastasis: a case report. Annals of Clinical and Translational Neurology. 2023;10(5):836-841. doi:10.1002/acn3.51766
BibTeX
@article{Lai2023,
author = {Lai, Mingyao and Li, Shaoqun and Li, Hainan and Hu, Qingjun and Li, Juan and Zhou, Jiangfen and Ai, Ruyu and Zhen, Junjie and Zhou, Zhaoming and Wang, Lichao and Zhang, Yangqiong and Hu, Wanming and Yuan, Li and Ma, Xuejiao and Zhang, Xing and Song, Chao and Li, Zhi and Cai, Linbo},
title = {Lorlatinib for ALK ‐fused, infant‐type hemispheric glioma with lung metastasis: a case report},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {5},
pages = {836--841},
doi = {10.1002/acn3.51766}
}
EUVIMED